NRx Pharma raises $6.5M, Q2 operating loss improves to $3.7M, FDA expands Fast Track for NRX-100

NRX Pharmaceuticals, Inc.

Registered direct offering of 3,959,999 shares at $1.65/sh raises ~$6.5M; one-year lockup, no warrants.
Q2 net loss $17.6M (vs $7.9M) on non-cash fair value changes; operating loss narrows to $3.7M (vs $7.1M).
FDA expanded Fast Track for NRX-100 to all depression types, addressing 13M Americans annually.
Cash balance $2.9M at June 30; with new capital expects to fund operations into 2026.
HOPE Therapeutics acquires Dura Medical, signs LOIs for NeuroSpa and Cohen and Associates; debt financing $7.8M approved.

item 1.01item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.